Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 204Neoplasms 119Breast Neoplasms 110Colorectal Neoplasms 97Ovarian Neoplasms 78Prostatic Neoplasms 77Neoplasm Metastasis 76Multiple Myeloma 65Lung Neoplasms 62Squamous Cell Carcinoma of Head and Neck 51Recurrence 49Endometrial Neoplasms 47Pancreatic Neoplasms 46Stomach Neoplasms 42Small Cell Lung Carcinoma 41Leukemia, Lymphocytic, Chronic, B-Cell 41Carcinoma, Renal Cell 41Melanoma 37Lymphoma, Non-Hodgkin 33Leukemia, Myeloid, Acute 33Triple Negative Breast Neoplasms 32Urinary Bladder Neoplasms 29Parkinson Disease 4, Autosomal Dominant Lewy Body 29Lymphoma, Follicular 29Lymphoma, Large B-Cell, Diffuse 28Carcinoma, Hepatocellular 28Head and Neck Neoplasms 26Advanced Solid Tumors 25Esophageal Neoplasms 24Lymphoma 23

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Angiomyolipoma × 30 days × Clear all
NCT05252585 2026-06-11

A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)

Novartis

Phase 4 Active not recruiting
4 enrolled

Tuberous Sclerosis, Angiomyolipoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡